Vol 11, Supp. A (2020)
Case report
Published online: 2021-01-07

open access

Page views 476
Article views/downloads 233
Get Citation

Connect on Social Media

Connect on Social Media

Successful nilotinib cessation after imatinib therapy failure

Joanna Wącław1, Tomasz Sacha1

Abstract

Successful treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKI) is nowadays likely to result in near-normal life expectancy. Nowadays, the treatment-free remission (TFR) is becoming more and more often a therapeutic goal for both hematologist and his patient. TKI discontinuation and maintenance of TFR is feasible in circa 40–50% of CML patients who achieved stable deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib therapy failure. After a few years of sustaining DMR nilotinib was discontinued. One year since this decision, the patient has remained in the TFR.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Hochhaus A, Larson RA, Guihot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376: 917–927.
  2. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29: 1123–1132.
  3. Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2251–2259.
  4. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10): 2197–2203.
  5. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2260–2270.
  6. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119: 1123–1129.
  7. Casado LF, García-Gutiérrez JV, Massagué I, et al. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. Cancer Med. 2015; 4(7): 995–1002.
  8. Steegmann JL, Baccarani M, Breccia M, et al. European Net recommendations for the management and avoidance of adverse event of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30: 1648–1671.
  9. Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009; 27(22): 3642–3649.
  10. Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018; 17(1): 49.
  11. Hochhaus A, Baccarani M, Silver RT, et al. European Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34: 966–984.
  12. Larson R, le Co, Reiffers J, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. ASCO Meeting Abstracts. 2008; 26: 6501.
  13. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, nonrandomised, trial. Lancet Oncol. 2018; 19(6): 747–57.
  14. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study . Leukemia. 2017; 31(7): 1525–1531.
  15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 3, 2020. https://www.nccn.org/patients/guidelines/content/PDF/cml-patient.pdf (September 20, 2020).
  16. Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018; 168(7): 461–470.



Hematology in Clinical Practice